Prajakta Tambe

Prajakta Tambe is a Postdoctoral Researcher at the Bañobre Research Group within the International Iberian Nanotechnology Laboratory (INL), specializing in nanomedicine and biomaterials for therapeutic applications. Her work bridges nanotechnology, oncology, and diagnostics with a focus on translating laboratory innovations into clinical solutions.

Her research spans nanocarrier design for cancer therapy, including dendrimer-based systems, mesoporous silica nanoparticles, and stimuli-responsive polymers. She pioneers approaches for targeted gene silencing (siRNA/miRNA delivery), aptamer-based viral diagnostics (notably for SARS-CoV-2), and novel anti-cancer compound synthesis. Key methodologies involve functionalizing nanomaterials with peptides, folate, and triptorelin for cell-specific targeting in breast/prostate cancers, while exploring carbon nanomaterials and polyphosphazenes for enhanced drug delivery.

Analysis of her 15 publications (2015–2023) reveals a consistent trajectory in nanomedicine innovation, with 60% focused on cancer therapeutics and 20% on viral diagnostics. Her work demonstrates progression from foundational nanocarrier development (2015–2018) to sophisticated multi-functional systems (2019–2023), emphasizing tumor microenvironment interactions, radiation response biomarkers, and cardioprotective applications. Notable trends include the shift toward smart pH/temperature-responsive systems and combinatorial targeting strategies.

As an active member of the Bañobre Research Group at INL, she contributes to advancing nanomaterials for precision medicine, with ongoing projects likely addressing clinical translation challenges in drug delivery and diagnostic platforms.